Cetero Research Adds DGD Research, Enhancing Their Therapeutic Capabilities and Expertise to Include Endocrinology and Metabolic Disorders
Since January 2006, Cetero has built a world-class team of early clinical and bioanalytical sites strategically located throughout North America, with six clinical sites in St. Louis, MO, Fargo, ND, East Grand Forks, MN, Miami, FL, Toronto, Ontario, Montreal, Quebec, and three bioanalytical laboratories in Houston, TX, Fargo, ND, and Toronto, Ontario.
Cetero currently has therapeutic capabilities in Immunology, Respiratory, Dermatology, Endocrinology and Cardiovascular. The addition of DGD Research to Cetero significantly increases access to patient populations with endocrinology and metabolic disorders, including: diabetes, heart disease, hypogonadism, growth hormone deficiency and hypothyroidism. The merger adds a new, 80,000 sq. ft. purpose-built research facility with 100 Phase I beds, with 12 dedicated Euglycemic/Hypoglycemic Clamp beds.
"The addition of DGD Research to the Cetero family provides unrivaled experience with patient populations to our Phase I-IV capabilities in therapeutic research, especially within the endocrinology and metabolic disorder areas," said Jerry Merritt, CEO of Cetero Research. "With more than 3,000 patients recruited each year to participate in clinical trials at the DGD clinic, the strong scientific rigor and patient-centered philosophy of DGD is core to the Cetero vision of today's research for tomorrow's healthcare."
Cetero's expertise is unparalleled in the early clinical research and bioanalytical industry with a foundation of more than 24 years of experience - offering a full spectrum of services from early clinical research through late stage to meet the needs of biotechnology, generic and pharmaceutical companies globally. Cetero provides quality research services including: clinical pharmacology, bioanalytical, integrated bioequivalence, cardiac safety, pre-clinical and clinical dermatology, environmental exposure chambers, central laboratory and late stage clinical trial management.
"Becoming part of the Cetero family of companies only enhances DGD's opportunity to positively impact the welfare and education of the public -- our original mission," said Sherwyn L. Schwartz, MD, CEO and CMO of DGD Research. "Joining Cetero will allow us to offer more comprehensive services to our clients, including: pharmacokinetics, pharmacodynamics, data management and report writing services."
Headquartered in San Antonio, TX, DGD Research was established in 1983 by Dr. Sherwyn L. Schwartz, M.D., as an addition to the Diabetes & Glandular Disease Clinic -- one of the largest endocrinology practices in the United States. With Drs. Jerome S. Fischer, M.D. and Mark S. Kipnes, M.D., DGD Research has performed more than 1,500 Phase I-IV clinical trials in diabetes, hypertension, neuropathy, osteoporosis, hypercholesterolemia, obesity, menopause, and nephropathy under the supervision of major pharmaceutical companies in accordance with FDA rules and regulations. Currently, DGD Research has two clinical sites in San Antonio and leads the U.S. market in Phase I endocrine/metabolic clinical trials and is fifth nationwide for Phase II-IV trials.
Cetero Research's corporate headquarters are located in Cary, NC. For more information on Cetero Research, please contact April Johnson at 919-468-4214 or visit www.cetero.com/dgd.
April Johnson, 919-468-4214
Posted: January 2008